Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Palisade Bio Inc (PALI)
Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,577
  • Shares Outstanding, K 9,217
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,260 K
  • 60-Month Beta 1.64
  • Price/Sales 12.04
  • Price/Cash Flow N/A
  • Price/Book 0.40
Trade PALI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.07
  • Most Recent Earnings -0.49 on 11/09/23
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +32.34%
on 11/09/23
0.6997 -5.43%
on 12/04/23
+0.0867 (+15.08%)
since 11/03/23
3-Month
0.5000 +32.34%
on 11/09/23
1.9300 -65.72%
on 09/06/23
-0.0003 (-0.05%)
since 09/01/23
52-Week
0.5000 +32.34%
on 11/09/23
8.5400 -92.25%
on 12/30/22
-3.5783 (-84.39%)
since 12/02/22

Most Recent Stories

More News
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0695 (-8.07%)
GRI : 0.7372 (-3.52%)
MBRX : 0.5926 (-2.85%)
XBIO : 3.53 (-0.56%)
AREC : 1.7000 (-1.16%)
CNSP : 2.18 (unch)
NVNO : 3.59 (+1.13%)
PALI : 0.6617 (+9.35%)
Palisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Palisade Bio, Inc. (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

PALI : 0.6617 (+9.35%)
Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

CRSP : 71.51 (+4.17%)
KALA : 6.49 (+6.74%)
KOD : 2.89 (+12.45%)
PALI : 0.6617 (+9.35%)
What Makes Palisade Bio, Inc. (PALI) a New Buy Stock

Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PALI : 0.6617 (+9.35%)
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEO : 15.00 (unch)
ETON : 3.66 (-1.08%)
IMCR : 51.97 (-1.27%)
PALI : 0.6617 (+9.35%)
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148

Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of

PALI : 0.6617 (+9.35%)
Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new...

PALI : 0.6617 (+9.35%)
Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for...

PALI : 0.6617 (+9.35%)
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant...

PALI : 0.6617 (+9.35%)
Palisade Bio to Present at the 2022 BIO International Convention

In-person presentation on Monday, June 13th at 1:45 PM PT...

PALI : 0.6617 (+9.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 0.8205
2nd Resistance Point 0.7601
1st Resistance Point 0.7109
Last Price 0.6617
1st Support Level 0.6013
2nd Support Level 0.5409
3rd Support Level 0.4917

See More

52-Week High 8.5400
Fibonacci 61.8% 5.4687
Fibonacci 50% 4.5200
Fibonacci 38.2% 3.5713
Last Price 0.6617
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar